Safely deliver ablative doses, with up to 100% reduction in grade 3+ toxicity
Delivering SBRT and hypofractionated radiation therapy using conventional technology has been shown to increase toxicity.1,2 However, studies show MRIdian SBRT significantly decreases toxicity.1,2 Patients may see up to 100% reduction in grade 3+ toxicity when treating oligomets.1,2
These outcomes are accomplished by:
- Delivering treatment with real-time MRI imaging.
- Providing daily on-table adaption to account for any changes in the position of the tumor and nearby organs-at-risk.
- Tracking the tumor in real-time, so clinicians can see the tumor throughout the treatment.
- Using real-time beam gating to protect surrounding healthy tissue and deliver an optimal dose to the tumor; when the tumor moves out of the target area, the beam automatically stops.
MRIdian Single Fraction Treatment
Patient: 65-year old male diagnosed with Stage-1 NSCLC
Treatment Options: Surgery vs. standard 5 fraction (Fx) SBRT (patient declined surgery)
Challenge: Infection risk to compromised cancer patient; similar patient would be treated in 5 Fx, increasing number of healthcare encounters (and risk of exposure to COVID-19 in these times)
MRIdian: Confidence to deliver 34 Gy in 1 Fx; breath-hold delivery with visual feedback to maintain chest wall dose constraints; 3 mm PTV margins, automated beam gating for intrafraction motion; total treatment time 40 min door-to-door
Outcome: Patient doing well, no acute toxicities reported, opportunity to treat multiple oligomets in different location efficiently with single fraction option
Case courtesy of Dr. Choung, Miami Cancer Institute. Results of this case study are not predictive of future results. The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for informational purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations
Where can I go for more information?
Please contact your healthcare provider with any questions or concerns.
Important Safety Information
Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.
Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.
1. Palma DA, Olson R, Harrow S, et al. (2019). Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet, 393(10185):2051–2058.
2. Henke, L., et al. (2018). Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 126(3), 519–526.